Kantarjian H - Search Results

1

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.

Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo CD, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA. Takahashi K, et al. Among authors: kantarjian h. Lancet Oncol. 2017 Jan;18(1):100-111. doi: 10.1016/S1470-2045(16)30626-X. Epub 2016 Dec 3. Lancet Oncol. 2017. PMID: 27923552 Free PMC article.

2

Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

Estey E, Thall P, Andreeff M, Beran M, Kantarjian H, O'Brien S, Escudier S, Robertson LE, Koller C, Kornblau S, et al. Estey E, et al. Among authors: kantarjian h. J Clin Oncol. 1994 Apr;12(4):671-8. doi: 10.1200/JCO.1994.12.4.671. J Clin Oncol. 1994. PMID: 7512125 Clinical Trial.

3

Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia.

Robertson LE, Estey E, Kantarjian H, Koller C, O'Brien S, Brown B, Keating MJ. Robertson LE, et al. Among authors: kantarjian h. Leukemia. 1994 Dec;8(12):2047-51. Leukemia. 1994. PMID: 7807993

4

Quesnel B, Kantarjian H, Bjergaard JP, Brault P, Estey E, Lai JL, Tilly H, Stoppa AM, Archimbaud E, Harousseau JL, et al. Quesnel B, et al. Among authors: kantarjian h. J Clin Oncol. 1993 Dec;11(12):2370-9. doi: 10.1200/JCO.1993.11.12.2370. J Clin Oncol. 1993. PMID: 8246025 Review.

5

Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work.

de Lima M, Strom SS, Keating M, Kantarjian H, Pierce S, O'Brien S, Freireich E, Estey E. de Lima M, et al. Among authors: kantarjian h. Blood. 1997 Dec 15;90(12):4719-24. Blood. 1997. PMID: 9389687 Free article.

6

Determinants of prognosis in late chronic-phase chronic myelogenous leukemia.

Rodriguez J, Cortes J, Smith T, O'Brien S, Rios MB, Talpaz M, Kantarjian H. Rodriguez J, et al. Among authors: kantarjian h. J Clin Oncol. 1998 Dec;16(12):3782-7. doi: 10.1200/JCO.1998.16.12.3782. J Clin Oncol. 1998. PMID: 9850022

7

Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.

Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M. Aguayo A, et al. Among authors: kantarjian h. Blood. 1999 Dec 1;94(11):3717-21. Blood. 1999. PMID: 10572084 Free article.

8

New developments in the treatment of acute myeloid leukemia: focus on topotecan.

Kantarjian H. Kantarjian H. Semin Hematol. 1999 Oct;36(4 Suppl 8):16-25. Semin Hematol. 1999. PMID: 10622225 Review.

9

Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.

Giles F, Cortes J, Garcia-Manero G, Kornblau S, Estey E, Kwari M, Murgo A, Kantarjian H. Giles F, et al. Among authors: kantarjian h. Invest New Drugs. 2001;19(1):13-20. doi: 10.1023/a:1006432012394. Invest New Drugs. 2001. PMID: 11291829 Clinical Trial.

10

BCR rearrangement-negative chronic myelogenous leukemia revisited.

Kurzrock R, Bueso-Ramos CE, Kantarjian H, Freireich E, Tucker SL, Siciliano M, Pilat S, Talpaz M. Kurzrock R, et al. Among authors: kantarjian h. J Clin Oncol. 2001 Jun 1;19(11):2915-26. doi: 10.1200/JCO.2001.19.11.2915. J Clin Oncol. 2001. PMID: 11387365

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

2,511 results

Search Page